L
Lars Fransecky
Researcher at Charité
Publications - 26
Citations - 724
Lars Fransecky is an academic researcher from Charité. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 16 publications receiving 459 citations.
Papers
More filters
Journal ArticleDOI
Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Uwe Platzbecker,Jan Moritz Middeke,Katja Sockel,Regina Herbst,Dominik Wolf,Dominik Wolf,Claudia D. Baldus,Uta Oelschlägel,Anke Mütherig,Lars Fransecky,Richard Noppeney,Gesine Bug,Katharina Götze,Alwin Krämer,Tilmann Bochtler,Matthias Stelljes,Christoph Groth,Antje Schubert,Marika Mende,Friedrich Stölzel,Christine Borkmann,A.S. Kubasch,Malte von Bonin,Hubert Serve,Mathias Hänel,Ulrich Dührsen,Johannes Schetelig,C. Röllig,Michael Kramer,Gerhard Ehninger,Martin Bornhäuser,Christian Thiede +31 more
TL;DR: This study suggests that continuous MRD negativity during regular MRD monitoring might be prognostic for patient outcomes and pre-emptive therapy with azacitidine can prevent or substantially delay haematological relapse in MRD-positive patients with MDS or AML who are at high risk of relapse.
Journal ArticleDOI
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
TL;DR: In this paper, the authors summarized key findings leading to aberrant activation of PI3K/AKT/mTOR pathways in acute leukemia and reflected on both promises and challenges of targeting PI3k/AKt/mtor in the acute leukemia setting.
Journal ArticleDOI
FLT3 mutations in early T-cell precursor ALL characterize a stem cell like leukemia and imply the clinical use of tyrosine kinase inhibitors.
Martin Neumann,Ebru Coskun,Lars Fransecky,Liliana H. Mochmann,Isabelle Bartram,Nasrin Farhadi Sartangi,Sandra Heesch,Nicola Gökbuget,Stefan Schwartz,Christian Brandts,Cornelia Schlee,Rainer Haas,Ulrich Dührsen,Martin Griesshammer,Hartmut Döhner,Gerhard Ehninger,Thomas Burmeister,Olga Blau,Eckhard Thiel,Dieter Hoelzer,Wolf-Karsten Hofmann,Claudia D. Baldus +21 more
TL;DR: FLT3 mutated ETP-ALL defines a molecular distinct stem cell like leukemic subtype and warrants clinical studies with the implementation of FLT3 inhibitors in addition to early allogeneic stem cell transplantation for this high risk subgroup.
Journal ArticleDOI
Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia
Christoph Röllig,Michael Kramer,Christoph Schliemann,Jan-Henrik Mikesch,Björn Steffen,Alwin Krämer,Richard Noppeney,Kerstin Schäfer-Eckart,Stefan W. Krause,Mathias Hänel,Regina Herbst,Volker Kunzmann,Hermann Einsele,Edgar Jost,Tim H. Brümmendorf,Sebastian Scholl,Andreas Hochhaus,Andreas Neubauer,Kristina Sohlbach,Lars Fransecky,Martin Kaufmann,Dirk Niemann,Markus Schaich,Norbert Frickhofen,Alexander Kiani,Frank Heits,Ulrich Krümpelmann,Ulrich Kaiser,Johannes Kullmer,Maxi Wass,Friedrich Stölzel,Malte von Bonin,Jan Moritz Middeke,Christian Thiede,Johannes Schetelig,Wolfgang E. Berdel,Gerhard Ehninger,Claudia D. Baldus,Carsten Müller-Tidow,Uwe Platzbecker,Hubert Serve,Martin Bornhäuser +41 more
TL;DR: The study suggests that TDT is not related to survival, and suggests that it may be a feasible approach to wait for genetic and other laboratory test results in order to assign clinically stable patients to the best available treatment option.
Journal ArticleDOI
Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.
Patricia Silva,Martin Neumann,Martin Neumann,Michael P Schroeder,Sebastian Vosberg,Sebastian Vosberg,Cornelia Schlee,Konstandina Isaakidis,Jutta Ortiz-Tanchez,Lars Fransecky,T. Hartung,Seval Türkmen,Alexander Graf,Stefan Krebs,Helmut Blum,Carsten Müller-Tidow,Christian Thiede,Christian Thiede,G. Ehninger,G. Ehninger,Hubert Serve,Hubert Serve,Jochen Hecht,Wolfgang E. Berdel,Philipp A. Greif,Philipp A. Greif,Christoph Röllig,Christoph Röllig,Claudia D. Baldus,Claudia D. Baldus +29 more
TL;DR: Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape that is distinct from other chronic leukemias in that it is driven by a single gene or molecule.